Clinical Trial Update: A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating baricitinib in children aged 2 to <18 years with juvenile idiopathic arthritis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2022-10-07